Merck's antiviral drug meets main goal in late-stage trial

October 19, 2016 11:48 AM

7 0

Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.

The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant.

Also read: House Passes Health Bill to Speed Drug Approvals, Boost Biomedical Research

Read more

To category page

Loading...